These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 28689240

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
    Staeck O, Slowinski T, Lieker I, Wu K, Rudolph B, Schmidt D, Brakemeier S, Neumayer HH, Wei C, Reiser J, Budde K, Halleck F, Khadzhynov D.
    Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
    [Abstract] [Full Text] [Related]

  • 3. Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.
    Kim EY, Roshanravan H, Dryer SE.
    Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2342-2354. PubMed ID: 28629718
    [Abstract] [Full Text] [Related]

  • 4. Soluble urokinase receptor and focal segmental glomerulosclerosis.
    Reiser J, Wei C, Tumlin J.
    Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):428-32. PubMed ID: 22569341
    [Abstract] [Full Text] [Related]

  • 5. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.
    Hahm E, Wei C, Fernandez I, Li J, Tardi NJ, Tracy M, Wadhwani S, Cao Y, Peev V, Zloza A, Lusciks J, Hayek SS, O'Connor C, Bitzer M, Gupta V, Sever S, Sykes DB, Scadden DT, Reiser J.
    Nat Med; 2017 Jan; 23(1):100-106. PubMed ID: 27941791
    [Abstract] [Full Text] [Related]

  • 6. RAGE and αVβ3-integrin are essential for suPAR signaling in podocytes.
    Kim EY, Dryer SE.
    Biochim Biophys Acta Mol Basis Dis; 2021 Oct 01; 1867(10):166186. PubMed ID: 34166766
    [Abstract] [Full Text] [Related]

  • 7. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
    Kronbichler A, Saleem MA, Meijers B, Shin JI.
    J Immunol Res; 2016 Oct 01; 2016():2068691. PubMed ID: 27504461
    [Abstract] [Full Text] [Related]

  • 8. A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease.
    Hayek SS, Koh KH, Grams ME, Wei C, Ko YA, Li J, Samelko B, Lee H, Dande RR, Lee HW, Hahm E, Peev V, Tracy M, Tardi NJ, Gupta V, Altintas MM, Garborcauskas G, Stojanovic N, Winkler CA, Lipkowitz MS, Tin A, Inker LA, Levey AS, Zeier M, Freedman BI, Kopp JB, Skorecki K, Coresh J, Quyyumi AA, Sever S, Reiser J.
    Nat Med; 2017 Aug 01; 23(8):945-953. PubMed ID: 28650456
    [Abstract] [Full Text] [Related]

  • 9. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
    Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J.
    Nat Med; 2011 Jul 31; 17(8):952-60. PubMed ID: 21804539
    [Abstract] [Full Text] [Related]

  • 10. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
    Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Zhao MH.
    BMC Med; 2014 May 20; 12():81. PubMed ID: 24884842
    [Abstract] [Full Text] [Related]

  • 11. Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.
    Alfano M, Cinque P, Giusti G, Proietti S, Nebuloni M, Danese S, D'Alessio S, Genua M, Portale F, Lo Porto M, Singhal PC, Rastaldi MP, Saleem MA, Mavilio D, Mikulak J.
    Sci Rep; 2015 Sep 18; 5():13647. PubMed ID: 26380915
    [Abstract] [Full Text] [Related]

  • 12. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
    Alachkar N, Wei C, Arend LJ, Jackson AM, Racusen LC, Fornoni A, Burke G, Rabb H, Kakkad K, Reiser J, Estrella MM.
    Transplantation; 2013 Oct 15; 96(7):649-56. PubMed ID: 23842190
    [Abstract] [Full Text] [Related]

  • 13. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
    Alachkar N, Li J, Matar D, Vujjini V, Alasfar S, Tracy M, Reiser J, Wei C.
    BMC Nephrol; 2018 Dec 17; 19(1):361. PubMed ID: 30558559
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Extrarenal determinants of kidney filter function.
    Hahm E, Peev V, Reiser J.
    Cell Tissue Res; 2017 Jul 17; 369(1):211-216. PubMed ID: 28560690
    [Abstract] [Full Text] [Related]

  • 16. Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
    Morath C, Wei C, Macher-Goeppinger S, Schwenger V, Zeier M, Reiser J.
    Am J Ther; 2013 Jul 17; 20(2):226-9. PubMed ID: 23466622
    [Abstract] [Full Text] [Related]

  • 17. Circulating permeability factor suPAR: from concept to discovery to clinic.
    Reiser J.
    Trans Am Clin Climatol Assoc; 2013 Jul 17; 124():133-8. PubMed ID: 23874017
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.